person · Reporting owner

Barbarosh Craig A.

Disclosed activity across 7 companies

Tapewire entity: 911
SEC CIK: 0001472457

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Bazaarvoice IncBV · Entity 169747	Director	February 01, 2018	February 05, 2018
Evolent Health, Inc.EVH · Entity 5492	Director	June 04, 2026	June 08, 2026
LIFECORE BIOMEDICAL, INC. \DE\LFCR · Entity 6447	Director	July 08, 2024	July 10, 2024
ModivCare IncMODV · Entity 76927	Director	December 23, 2024	January 03, 2025
NEXTGEN HEALTHCARE, INC.NXGN · Entity 108396	Director	November 09, 2023	November 13, 2023
Sabra Health Care REIT, Inc.SBRA · Entity 886	Director	August 31, 2026	September 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Bazaarvoice Inc

Report date February 01, 2018 · Filed February 05, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2018-02-01 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2018-02-01 · Disposition to issuer · Disposed 1,720 · Balance 18,920 F1: Disposed of pursuant to the Agreement and Plan of Merger, by and among BV Parent, LLC, BV Merger Sub, Inc. and Bazaarvoice, Inc. (the "Issuer"), dated November 26, 2017 (as amended, the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $5.50 per share. Row 2 · 2018-02-01 · Disposition to issuer · Disposed 18,920 · Balance 0 F2: Disposed of pursuant to the Merger Agreement, whereby unvested shares of restricted stock were cancelled in exchange for cash payments in the amount of $5.50 per share.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger, by and among BV Parent, LLC, BV Merger Sub, Inc. and Bazaarvoice, Inc. (the "Issuer"), dated November 26, 2017 (as amended, the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $5.50 per share.

F2: Disposed of pursuant to the Merger Agreement, whereby unvested shares of restricted stock were cancelled in exchange for cash payments in the amount of $5.50 per share.

Evolent Health, Inc.

Report date June 04, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	95,031	Reported balance After 2026-06-04 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-04 · Grant · Acquired 41,096 · Balance 95,031 F1: Represents restricted stock units granted to Mr. Barbarosh pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2: Securities vest on the earlier of June 4, 2027, and the date of the Company's 2027 annual meeting, subject to the reporting person's continued service on the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units granted to Mr. Barbarosh pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2: Securities vest on the earlier of June 4, 2027, and the date of the Company's 2027 annual meeting, subject to the reporting person's continued service on the vesting date.

LIFECORE BIOMEDICAL, INC. \DE\

Report date July 08, 2024 · Filed July 10, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectIn Trust	88,073	Reported balance After 2024-07-08 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2024-07-08 · Grant · Acquired 30,000 · Balance 88,073 F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

ModivCare Inc

Report date December 23, 2024 · Filed January 03, 2025

This filing explicitly reported no securities owned.

NEXTGEN HEALTHCARE, INC.

Report date November 09, 2023 · Filed November 13, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnotes	0	Reported balance After 2023-11-09 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2023-11-09 · Disposition to issuer · Disposed 67,269 · Balance 0 F1: Includes 10,086 outstanding vested shares of restricted stock. F2: Pursuant to the Agreement and Plan of Merger, dated September 5, 2023, by and among the Issuer, Next Holdco Co., LLC ("Next Holdco") and Next Merger Sub, Inc. ("Merger Sub"), the Issuer became a wholly owned subsidiary of Next Holdco upon consummation of the merger with Merger Sub on November 9, 2023 (the "Effective Time"). At the Effective Time: (a) each of the Issuer's outstanding shares of common stock, each outstanding restricted stock unit and each outstanding deferred stock unit was cancelled and automatically converted into the right to receive $23.95 in cash; (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was cancelled and converted into the right to receive $23.95 in cash less the applicable per share exercise price; and (c) each of the Issuer's outstanding performance stock units was cancelled and converted into the right to receive $23.95 (with respect to the Issuer shares underlying the portion of such award which had F3: (Continued from footnote 2) vested), and, with respect to any portion of such award the vesting of which remained subject to achievement of performance objectives as of October 4, 2023, $23.95 for each Issuer share underlying the portion of the award that would vest as a result of the Merger in accordance with the terms and conditions of the applicable award agreement, which for the units granted in 2020 assumed performance achievement at the "maximum" level; for the units granted in 2021, assumed performance achievement above "target" with partial achievement of the next stock price hurdle; and for the units granted in 2022, assumed performance achievement at 140% of the "target" level. F4: The ownership form includes both direct and indirect holdings. F5: Indirect ownership includes the holdings of the The Barbarosh Family Trust established May 29, 2007.
Deferred Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2023-11-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-11-09 · Disposition to issuer · Disposed 9,483 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated September 5, 2023, by and among the Issuer, Next Holdco Co., LLC ("Next Holdco") and Next Merger Sub, Inc. ("Merger Sub"), the Issuer became a wholly owned subsidiary of Next Holdco upon consummation of the merger with Merger Sub on November 9, 2023 (the "Effective Time"). At the Effective Time: (a) each of the Issuer's outstanding shares of common stock, each outstanding restricted stock unit and each outstanding deferred stock unit was cancelled and automatically converted into the right to receive $23.95 in cash; (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was cancelled and converted into the right to receive $23.95 in cash less the applicable per share exercise price; and (c) each of the Issuer's outstanding performance stock units was cancelled and converted into the right to receive $23.95 (with respect to the Issuer shares underlying the portion of such award which had F3: (Continued from footnote 2) vested), and, with respect to any portion of such award the vesting of which remained subject to achievement of performance objectives as of October 4, 2023, $23.95 for each Issuer share underlying the portion of the award that would vest as a result of the Merger in accordance with the terms and conditions of the applicable award agreement, which for the units granted in 2020 assumed performance achievement at the "maximum" level; for the units granted in 2021, assumed performance achievement above "target" with partial achievement of the next stock price hurdle; and for the units granted in 2022, assumed performance achievement at 140% of the "target" level. F6: The Deferred Stock Units credited under the Deferred Compensation Plan are generally payable in the form elected or provided under the Deferred Compensation Plan on the earlier of (i) the date or event elected by the reporting person, (ii) within 90 days following the participant's separation from service as defined under the Deferred Compensation Plan, or (ii) upon death, disability or change in control as defined under the Deferred Compensation Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 10,086 outstanding vested shares of restricted stock.

F2: Pursuant to the Agreement and Plan of Merger, dated September 5, 2023, by and among the Issuer, Next Holdco Co., LLC ("Next Holdco") and Next Merger Sub, Inc. ("Merger Sub"), the Issuer became a wholly owned subsidiary of Next Holdco upon consummation of the merger with Merger Sub on November 9, 2023 (the "Effective Time"). At the Effective Time: (a) each of the Issuer's outstanding shares of common stock, each outstanding restricted stock unit and each outstanding deferred stock unit was cancelled and automatically converted into the right to receive $23.95 in cash; (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was cancelled and converted into the right to receive $23.95 in cash less the applicable per share exercise price; and (c) each of the Issuer's outstanding performance stock units was cancelled and converted into the right to receive $23.95 (with respect to the Issuer shares underlying the portion of such award which had

F3: (Continued from footnote 2) vested), and, with respect to any portion of such award the vesting of which remained subject to achievement of performance objectives as of October 4, 2023, $23.95 for each Issuer share underlying the portion of the award that would vest as a result of the Merger in accordance with the terms and conditions of the applicable award agreement, which for the units granted in 2020 assumed performance achievement at the "maximum" level; for the units granted in 2021, assumed performance achievement above "target" with partial achievement of the next stock price hurdle; and for the units granted in 2022, assumed performance achievement at 140% of the "target" level.

F4: The ownership form includes both direct and indirect holdings.

F5: Indirect ownership includes the holdings of the The Barbarosh Family Trust established May 29, 2007.

F6: The Deferred Stock Units credited under the Deferred Compensation Plan are generally payable in the form elected or provided under the Deferred Compensation Plan on the earlier of (i) the date or event elected by the reporting person, (ii) within 90 days following the participant's separation from service as defined under the Deferred Compensation Plan, or (ii) upon death, disability or change in control as defined under the Deferred Compensation Plan.

Sabra Health Care REIT, Inc.

Report date August 31, 2026 · Filed September 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	54,580	Reported balance After 2026-08-31 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-08-31 · Grant · Acquired 791 · Balance 54,580 F1: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2: Consists of 7,027 unvested stock units and 47,553 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock.
Common StockSEC Table I · non-derivative	IndirectBy The Barbarosh Family Trust	104,453	Reported balance Holding disclosure · report date 2026-08-31 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 104,453

Filing footnotes · ownership attribution and instrument terms

F1: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate.

F2: Consists of 7,027 unvested stock units and 47,553 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARATANA THERAPEUTICS, INC.

Report date July 18, 2019 · Filed July 18, 2019

Section 16 reporting ended · disclosed 2019-07-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-07-18 transaction · row 1 1 source row Row 1 · 2019-07-18 · Disposition to issuer · Disposed 4,500 · Balance 0 F1: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2) F2: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of all outstanding unvested Company restricted stock awards was accelerated in full and each such restricted stock award was cancelled and terminated as of the effective time of the Merger. Each holder of a Company restricted stock award received the right to the Merger Consideration due with respect to the shares of Company common stock received in exchange for such accelerated restricted stock awards.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.34	Direct	Reported balance After 2019-07-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-07-18 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80	Direct	Reported balance After 2019-07-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-07-18 · Disposition to issuer · Disposed 7,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares.

Filing footnotes · ownership attribution and instrument terms

F1: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2)

F2: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration").

F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of all outstanding unvested Company restricted stock awards was accelerated in full and each such restricted stock award was cancelled and terminated as of the effective time of the Merger. Each holder of a Company restricted stock award received the right to the Merger Consideration due with respect to the shares of Company common stock received in exchange for such accelerated restricted stock awards.

F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 31, 2026 Filed Sep 2, 2026 21:34 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	791	$0.00	$0.00	Disclosure SEC source: 0001472457-26-000010 · wk-form4_1788384867.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,580 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 7,027 unvested stock units and 47,553 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
June 17, 2026 Filed Jun 18, 2026 22:33 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	8,310	$0.00	$0.00	Disclosure SEC source: 0001472457-26-000008 · wk-form4_1781822014.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,326 F1 · shares: Grant of restricted stock units under the Issuer's 2009 Performance Incentive Plan. The units vest in equal monthly installments beginning July 17, 2026 and ending on the earlier of June 17, 2027 or the day before the date of the next annual stockholders' meeting. F2 · balance_after: Consists of 8,310 unvested stock units and 55,016 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
June 04, 2026 Filed Jun 8, 2026 20:19 UTC	Evolent Health, Inc. EVH · Entity 5492	GrantClass A Common Stock	41,096	$0.00	$0.00	Disclosure SEC source: 0001628908-26-000039 · wk-form4_1780949984.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,031 F1 · security: Represents restricted stock units granted to Mr. Barbarosh pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 4, 2027, and the date of the Company's 2027 annual meeting, subject to the reporting person's continued service on the vesting date. Read SEC document
May 29, 2026 Filed Jun 2, 2026 19:13 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	817	$0.00	$0.00	Disclosure SEC source: 0001472457-26-000004 · wk-form4_1780427606.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,016 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 726 unvested stock units and 54,290 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
February 27, 2026 Filed Mar 3, 2026 19:24 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	781	$0.00	$0.00	Disclosure SEC source: 0001472457-26-000002 · wk-form4_1772565886.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,199 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 2,854 unvested stock units and 51,345 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
November 28, 2025 Filed Dec 2, 2025 20:23 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	808	$0.00	$0.00	Disclosure SEC source: 0001472457-25-000007 · wk-form4_1764706992.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,418 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 4,921 unvested stock units and 48,497 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
August 29, 2025 Filed Sep 3, 2025 18:11 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	813	$0.00	$0.00	Disclosure SEC source: 0001472457-25-000005 · wk-form4_1756923058.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,610 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 6,922 unvested stock units and 45,688 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
June 12, 2025 Filed Jun 13, 2025 20:52 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	8,178	$0.00	$0.00	Disclosure SEC source: 0001976617-25-000076 · wk-form4_1749847929.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,797 F1 · shares: Grant of restricted stock units under the Issuer's 2009 Performance Incentive Plan. The units vest in equal monthly installments beginning July 12, 2025 and ending on the earlier of June 12, 2026 or the day before the date of the next annual stockholders' meeting. F2 · balance_after: Consists of 8,178 unvested stock units and 43,619 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
June 05, 2025 Filed Jun 9, 2025 11:10 UTC	Evolent Health, Inc. EVH · Entity 5492	GrantClass A Common Stock	21,979	$0.00	$0.00	Disclosure SEC source: 0001628908-25-000082 · wk-form4_1749467441.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,935 F1 · security: Represents restricted stock units granted to Mr. Barbarosh pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 5, 2026, and the date of the Company's 2026 annual meeting, subject to the reporting person's continued service on the vesting date. Read SEC document
May 30, 2025 Filed Jun 3, 2025 20:21 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	914	$0.00	$0.00	Disclosure SEC source: 0001976617-25-000063 · wk-form4_1748982066.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,197 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 847 unvested stock units and 53,350 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
March 06, 2025 Filed Mar 10, 2025 12:02 UTC	Evolent Health, Inc. EVH · Entity 5492	PurchaseClass A Common Stock	2,000	$8.81	$17,620.00	Disclosure SEC source: 0001628908-25-000036 · wk-form4_1741608122.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,956 F1 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document
February 28, 2025 Filed Mar 4, 2025 19:46 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	946	$0.00	$0.00	Disclosure SEC source: 0001976617-25-000034 · wk-form4_1741117585.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,283 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 3,328 unvested stock units and 49,955 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
November 29, 2024 Filed Dec 3, 2024 22:33 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	826	$0.00	$0.00	Disclosure SEC source: 0001862128-24-000042 · wk-form4_1733265173.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,508 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 5,718 unvested stock units and 47,790 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
August 30, 2024 Filed Sep 5, 2024 00:53 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	889	$0.00	$0.00	Disclosure SEC source: 0001976617-24-000077 · wk-form4_1725497558.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,770 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 8,039 unvested stock units and 45,731 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
July 08, 2024 Filed Jul 10, 2024 23:53 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447	GrantCommon Stock	30,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-24-031636 · wk-form4_1720655620.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · In Trust Disclosed balance after: 88,073 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration. Read SEC document
June 13, 2024 Filed Jun 17, 2024 19:33 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	9,480	$0.00	$0.00	Disclosure SEC source: 0001976617-24-000055 · wk-form4_1718652798.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,113 F1 · shares: Grant of restricted stock units under the Issuer's 2009 Performance Incentive Plan. The units vest in equal monthly installments beginning July 13, 2024 and ending on the earlier of June 13, 2025 or the day before the date of the next annual stockholders' meeting. F2 · balance_after: Consists of 9,480 unvested stock units and 53,633 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
June 06, 2024 Filed Jun 10, 2024 23:31 UTC	Evolent Health, Inc. EVH · Entity 5492	GrantClass A Common Stock	7,709	$0.00	$0.00	Disclosure SEC source: 0001628908-24-000069 · wk-form4_1718062292.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,956 F1 · security: Represents restricted stock units granted to Mr. Barbarosh pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 6, 2025, and the date of the Company's 2025 annual meeting, subject to the reporting person's continued service on the vesting date. Read SEC document
May 31, 2024 Filed Jun 4, 2024 22:42 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	1,011	$0.00	$0.00	Disclosure SEC source: 0001976617-24-000041 · wk-form4_1717540918.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,633 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 1,035 unvested stock units and 52,598 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
February 29, 2024 Filed Mar 4, 2024 18:36 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	1,040	$0.00	$0.00	Disclosure SEC source: 0001862128-24-000016 · wk-form4_1709577364.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,906 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 4,052 unvested stock units and 49,854 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
February 01, 2024 Filed Feb 2, 2024 23:30 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447	Exercise / conversionRestricted Stock Unit · Derivative	9,554	$0.00	$0.00	Disclosure SEC source: 0001628280-24-003126 · wk-form4_1706916605.xml · derivative · entry 2 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · In Trust Disclosed balance after: 0 Underlying: Common Stock · 9,554 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted Stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · derivative.expiration_date: The restricted stock units vested on February 1, 2024. Read SEC document
February 01, 2024 Filed Feb 2, 2024 23:30 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447	Exercise / conversionCommon Stock	9,554	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-24-003126 · wk-form4_1706916605.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · In Trust Disclosed balance after: 58,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted Stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. Read SEC document
November 30, 2023 Filed Dec 4, 2023 19:37 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	967	$0.00	$0.00	Disclosure SEC source: 0001976617-23-000050 · wk-form4_1701718651.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,079 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 6,939 unvested stock units and 47,140 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
November 09, 2023 Filed Nov 13, 2023 16:38 UTC	NEXTGEN HEALTHCARE, INC. NXGN · Entity 108396	Disposition to issuerDeferred Stock Units · Derivative	9,483	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-23-063056 · ownership.xml · derivative · entry 2 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,483 shares Expires not disclosed F2 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated September 5, 2023, by and among the Issuer, Next Holdco Co., LLC ("Next Holdco") and Next Merger Sub, Inc. ("Merger Sub"), the Issuer became a wholly owned subsidiary of Next Holdco upon consummation of the merger with Merger Sub on November 9, 2023 (the "Effective Time"). At the Effective Time: (a) each of the Issuer's outstanding shares of common stock, each outstanding restricted stock unit and each outstanding deferred stock unit was cancelled and automatically converted into the right to receive $23.95 in cash; (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was cancelled and converted into the right to receive $23.95 in cash less the applicable per share exercise price; and (c) each of the Issuer's outstanding performance stock units was cancelled and converted into the right to receive $23.95 (with respect to the Issuer shares underlying the portion of such award which had F3 · derivative.exercise_price: (Continued from footnote 2) vested), and, with respect to any portion of such award the vesting of which remained subject to achievement of performance objectives as of October 4, 2023, $23.95 for each Issuer share underlying the portion of the award that would vest as a result of the Merger in accordance with the terms and conditions of the applicable award agreement, which for the units granted in 2020 assumed performance achievement at the "maximum" level; for the units granted in 2021, assumed performance achievement above "target" with partial achievement of the next stock price hurdle; and for the units granted in 2022, assumed performance achievement at 140% of the "target" level. F2 · price: Pursuant to the Agreement and Plan of Merger, dated September 5, 2023, by and among the Issuer, Next Holdco Co., LLC ("Next Holdco") and Next Merger Sub, Inc. ("Merger Sub"), the Issuer became a wholly owned subsidiary of Next Holdco upon consummation of the merger with Merger Sub on November 9, 2023 (the "Effective Time"). At the Effective Time: (a) each of the Issuer's outstanding shares of common stock, each outstanding restricted stock unit and each outstanding deferred stock unit was cancelled and automatically converted into the right to receive $23.95 in cash; (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was cancelled and converted into the right to receive $23.95 in cash less the applicable per share exercise price; and (c) each of the Issuer's outstanding performance stock units was cancelled and converted into the right to receive $23.95 (with respect to the Issuer shares underlying the portion of such award which had F3 · price: (Continued from footnote 2) vested), and, with respect to any portion of such award the vesting of which remained subject to achievement of performance objectives as of October 4, 2023, $23.95 for each Issuer share underlying the portion of the award that would vest as a result of the Merger in accordance with the terms and conditions of the applicable award agreement, which for the units granted in 2020 assumed performance achievement at the "maximum" level; for the units granted in 2021, assumed performance achievement above "target" with partial achievement of the next stock price hurdle; and for the units granted in 2022, assumed performance achievement at 140% of the "target" level. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated September 5, 2023, by and among the Issuer, Next Holdco Co., LLC ("Next Holdco") and Next Merger Sub, Inc. ("Merger Sub"), the Issuer became a wholly owned subsidiary of Next Holdco upon consummation of the merger with Merger Sub on November 9, 2023 (the "Effective Time"). At the Effective Time: (a) each of the Issuer's outstanding shares of common stock, each outstanding restricted stock unit and each outstanding deferred stock unit was cancelled and automatically converted into the right to receive $23.95 in cash; (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was cancelled and converted into the right to receive $23.95 in cash less the applicable per share exercise price; and (c) each of the Issuer's outstanding performance stock units was cancelled and converted into the right to receive $23.95 (with respect to the Issuer shares underlying the portion of such award which had F3 · derivative.exercise_date: (Continued from footnote 2) vested), and, with respect to any portion of such award the vesting of which remained subject to achievement of performance objectives as of October 4, 2023, $23.95 for each Issuer share underlying the portion of the award that would vest as a result of the Merger in accordance with the terms and conditions of the applicable award agreement, which for the units granted in 2020 assumed performance achievement at the "maximum" level; for the units granted in 2021, assumed performance achievement above "target" with partial achievement of the next stock price hurdle; and for the units granted in 2022, assumed performance achievement at 140% of the "target" level. F6 · derivative.expiration_date: The Deferred Stock Units credited under the Deferred Compensation Plan are generally payable in the form elected or provided under the Deferred Compensation Plan on the earlier of (i) the date or event elected by the reporting person, (ii) within 90 days following the participant's separation from service as defined under the Deferred Compensation Plan, or (ii) upon death, disability or change in control as defined under the Deferred Compensation Plan. Read SEC document
November 09, 2023 Filed Nov 13, 2023 16:38 UTC	NEXTGEN HEALTHCARE, INC. NXGN · Entity 108396	Disposition to issuerCommon Stock	67,269	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-23-063056 · ownership.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 F1 · shares: Includes 10,086 outstanding vested shares of restricted stock. F2 · price: Pursuant to the Agreement and Plan of Merger, dated September 5, 2023, by and among the Issuer, Next Holdco Co., LLC ("Next Holdco") and Next Merger Sub, Inc. ("Merger Sub"), the Issuer became a wholly owned subsidiary of Next Holdco upon consummation of the merger with Merger Sub on November 9, 2023 (the "Effective Time"). At the Effective Time: (a) each of the Issuer's outstanding shares of common stock, each outstanding restricted stock unit and each outstanding deferred stock unit was cancelled and automatically converted into the right to receive $23.95 in cash; (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was cancelled and converted into the right to receive $23.95 in cash less the applicable per share exercise price; and (c) each of the Issuer's outstanding performance stock units was cancelled and converted into the right to receive $23.95 (with respect to the Issuer shares underlying the portion of such award which had F3 · price: (Continued from footnote 2) vested), and, with respect to any portion of such award the vesting of which remained subject to achievement of performance objectives as of October 4, 2023, $23.95 for each Issuer share underlying the portion of the award that would vest as a result of the Merger in accordance with the terms and conditions of the applicable award agreement, which for the units granted in 2020 assumed performance achievement at the "maximum" level; for the units granted in 2021, assumed performance achievement above "target" with partial achievement of the next stock price hurdle; and for the units granted in 2022, assumed performance achievement at 140% of the "target" level. F4 · ownership.nature: The ownership form includes both direct and indirect holdings. F5 · ownership.nature: Indirect ownership includes the holdings of the The Barbarosh Family Trust established May 29, 2007. Read SEC document
August 31, 2023 Filed Sep 5, 2023 22:36 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	1,101	$0.00	$0.00	Disclosure SEC source: 0001862128-23-000040 · wk-form4_1693953357.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,977 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 9,712 unvested stock units and 44,265 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
August 22, 2023 Filed Aug 23, 2023 16:06 UTC	NEXTGEN HEALTHCARE, INC. NXGN · Entity 108396	GrantCommon Stock	10,086	$16.36	$165,006.96	Disclosure SEC source: 0001209191-23-047019 · doc4.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,269 Read SEC document
June 14, 2023 Filed Jun 16, 2023 23:22 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	11,382	$0.00	$0.00	Disclosure SEC source: 0001976617-23-000031 · wk-form4_1686957618.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,326 F1 · shares: Grant of restricted stock units under the Issuer's 2009 Performance Incentive Plan. The units vest in equal monthly installments beginning July 14, 2023 and ending on the earlier of June 14, 2024 or the day before the date of the next annual stockholders' meeting. F2 · balance_after: Consists of 11,382 unvested stock units and 49,944 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
June 08, 2023 Filed Jun 12, 2023 21:22 UTC	Evolent Health, Inc. EVH · Entity 5492	GrantClass A Common Stock	5,049	$0.00	$0.00	Disclosure SEC source: 0001628908-23-000087 · wf-form4_168660492615314.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,247 F1 · security: Represents restricted stock units granted to Mr. Barbarosh pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 8, 2024 and the date of the Company's 2024 annual meeting, subject to the reporting person's continued service on the vesting date. Read SEC document
June 01, 2023 Filed Jun 5, 2023 19:32 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447	GrantCommon Stock	18,182	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-23-020846 · wk-form4_1685993517.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · In Trust Disclosed balance after: 48,519 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: Restricted Stock Units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2024 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from Grant Date). Read SEC document
May 31, 2023 Filed Jun 1, 2023 22:50 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447	Exercise / conversionRestricted Stock Unit · Derivative	9,474	$0.00	$0.00	Disclosure SEC source: 0001628280-23-020576 · wk-form4_1685659799.xml · derivative · entry 2 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · In Trust Disclosed balance after: 0 Underlying: Common Stock · 9,474 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · derivative.exercise_date: The restricted stock units vested on May 31, 2023. F2 · derivative.expiration_date: The restricted stock units vested on May 31, 2023. Read SEC document
May 31, 2023 Filed Jun 1, 2023 22:50 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447	Exercise / conversionCommon Stock	9,474	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-23-020576 · wk-form4_1685659799.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · In Trust Disclosed balance after: 30,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: The restricted stock units vested on May 31, 2023. Read SEC document
May 31, 2023 Filed Jun 2, 2023 21:24 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	1,092	$0.00	$0.00	Disclosure SEC source: 0001976617-23-000015 · wf-form4_168574107282665.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,944 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Includes 804 unvested stock units and 49,140 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
February 28, 2023 Filed Mar 3, 2023 00:06 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	1,010	$0.00	$0.00	Disclosure SEC source: 0001862128-23-000026 · wf-form4_167780198894650.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,985 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 3,123 unvested stock units and 46,862 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
February 01, 2023 Filed Feb 2, 2023 22:29 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447	GrantRestricted Stock Unit · Derivative	9,554	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-23-002094 · wf-form4_167537694667098.xml · derivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · In Trust Disclosed balance after: 9,554 Underlying: Common Stock · 9,554 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F1 · price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document
November 30, 2022 Filed Dec 2, 2022 22:11 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	909	$0.00	$0.00	Disclosure SEC source: 0001862128-22-000101 · wf-form4_167001907803570.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,040 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 5,329 unvested stock units and 44,711 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
September 01, 2022 Filed Sep 2, 2022 16:07 UTC	NEXTGEN HEALTHCARE, INC. NXGN · Entity 108396	SaleCommon Stock	3,500	$17.27	$60,430.65	Disclosure SEC source: 0001209191-22-048479 · doc4.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,183 F1 · kind: Pursuant to a 10b5-1(c) plan adopted by the reporting person on February 28, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.12 to $17.34. Full information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or its stockholders upon request. Read SEC document
August 31, 2022 Filed Sep 2, 2022 20:03 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	768	$0.00	$0.00	Disclosure SEC source: 0001862128-22-000079 · wf-form4_166214900391711.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,042 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 7,439 unvested stock units and 42,603 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
August 17, 2022 Filed Aug 18, 2022 16:44 UTC	NEXTGEN HEALTHCARE, INC. NXGN · Entity 108396	GrantDeferred Stock Units · Derivative	9,483	$0.00	$0.00	Disclosure SEC source: 0001209191-22-046656 · doc4.xml · derivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,483 Underlying: Common Shares · 9,483 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Stock Unit is economically equivalent to one share of Common Stock. F2 · shares: Deferred Stock Units credited to the reporting person under the NextGen Healthcare, Inc. Deferred Compensation Plan for Non-Employee Directors (the "Deferred Compensation Plan"), which includes voluntary deferred compensation. F3 · derivative.exercise_date: The Deferred Stock Units credited under the Deferred Compensation Plan are generally payable in the form elected or provided under the Deferred Compensation Plan on the earlier of (i) the date or event elected by the reporting person, (ii) within 90 days following the participant's separation from service as defined under the Deferred Compensation Plan, or (ii) upon death, disability or change in control as defined under the Deferred Compensation Plan. F3 · derivative.expiration_date: The Deferred Stock Units credited under the Deferred Compensation Plan are generally payable in the form elected or provided under the Deferred Compensation Plan on the earlier of (i) the date or event elected by the reporting person, (ii) within 90 days following the participant's separation from service as defined under the Deferred Compensation Plan, or (ii) upon death, disability or change in control as defined under the Deferred Compensation Plan. Read SEC document
August 01, 2022 Filed Aug 2, 2022 16:04 UTC	NEXTGEN HEALTHCARE, INC. NXGN · Entity 108396	SaleCommon Stock	3,500	$17.35	$60,717.65	Disclosure SEC source: 0001209191-22-043838 · doc4.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,683 F1 · kind: Pursuant to a 10b5-1(c) plan adopted by the reporting person on February 28, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.045 to $17.59. Full information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or its stockholders upon request. Read SEC document
July 01, 2022 Filed Jul 5, 2022 16:32 UTC	NEXTGEN HEALTHCARE, INC. NXGN · Entity 108396	SaleCommon Stock	3,500	$17.39	$60,873.05	Disclosure SEC source: 0001209191-22-040712 · doc4.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,183 F1 · kind: Pursuant to a 10b5-1(c) plan adopted by the reporting person on February 28, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.215 to $17.59. Full information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or its stockholders upon request. Read SEC document
June 14, 2022 Filed Jun 16, 2022 16:23 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	8,751	$0.00	$0.00	Disclosure SEC source: 0001862128-22-000059 · wf-form4_165539659591453.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,736 F1 · shares: Grant of restricted stock units under the Issuer's 2009 Performance Incentive Plan. The units vest in equal monthly installments beginning July 14, 2022 and ending on the earlier of June 14, 2023 or the day before the date of the next annual stockholders' meeting. F2 · balance_after: Consists of 8,751 unvested stock units and 47,985 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
June 09, 2022 Filed Jun 13, 2022 22:04 UTC	Evolent Health, Inc. EVH · Entity 5492	GrantClass A Common Stock	5,564	$0.00	$0.00	Disclosure SEC source: 0001628908-22-000071 · wf-form4_165515783970435.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,198 F1 · security: Represents restricted stock units granted to Mr. Barbarosh pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 9, 2023 and the date of the company's 2023 annual meeting, subject to the reporting person's continued service on the vesting date. Read SEC document
June 04, 2022 Filed Jun 7, 2022 21:17 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	Exercise / conversionRestricted Stock Unit · Derivative	7,059	$9.50	$67,060.50	Disclosure SEC source: 0001628280-22-016488 · wf-form4_165463665103342.xml · derivative · entry 2 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · In Trust Disclosed balance after: 0 Underlying: Common Stock · 7,059 shares Expires 2022-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on June 4, 2021. F3 · derivative.exercise_date: The restricted stock units vested on June 4, 2022. F3 · derivative.expiration_date: The restricted stock units vested on June 4, 2022. Read SEC document
June 04, 2022 Filed Jun 7, 2022 21:17 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantCommon Stock	7,059	$9.50	$67,060.50	Disclosure SEC source: 0001628280-22-016488 · wf-form4_165463665103342.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · In Trust Disclosed balance after: 20,863 F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document
June 01, 2022 Filed Jun 2, 2022 17:33 UTC	NEXTGEN HEALTHCARE, INC. NXGN · Entity 108396	SaleCommon Stock	3,500	$18.17	$63,580.65	Disclosure SEC source: 0001209191-22-033655 · doc4.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,683 F1 · kind: Pursuant to a 10b5-1(c) plan adopted by the reporting person on February 28, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.08 to $18.30. Full information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or its stockholders upon request. Read SEC document
May 31, 2022 Filed Jun 2, 2022 16:45 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantRestricted Stock Unit · Derivative	9,474	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-22-016007 · wf-form4_165418832044094.xml · derivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · In Trust Disclosed balance after: 9,474 Underlying: Common Stock · 9,474 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document
May 31, 2022 Filed Jun 2, 2022 20:14 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	759	$0.00	$0.00	Disclosure SEC source: 0001862128-22-000045 · wf-form4_165420085638756.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,985 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 587 unvested stock units and 47,398 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
May 02, 2022 Filed May 3, 2022 17:07 UTC	NEXTGEN HEALTHCARE, INC. NXGN · Entity 108396	SaleCommon Stock	3,500	$19.01	$66,519.60	Disclosure SEC source: 0001209191-22-026799 · doc4.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,183 F1 · kind: Pursuant to a 10b5-1(c) plan adopted by the reporting person on February 28, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.75 to $19.22. Full information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or its stockholders upon request. Read SEC document
April 01, 2022 Filed Apr 4, 2022 16:34 UTC	NEXTGEN HEALTHCARE, INC. NXGN · Entity 108396	SaleCommon Stock	3,500	$21.27	$74,435.55	Disclosure SEC source: 0001209191-22-022416 · doc4.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,683 F1 · kind: Pursuant to a 10b5-1(c) plan adopted by the reporting person on February 28, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.91 to $21.71. Full information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or its stockholders upon request. Read SEC document
February 28, 2022 Filed Mar 2, 2022 01:25 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	776	$0.00	$0.00	Disclosure SEC source: 0001862128-22-000021 · wf-form4_164618432239851.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,942 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 2,288 unvested stock units and 45,654 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.